Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
-
New hope for hepatitis b: experimental combo aims to clear the virus
Disease control CompletedThis study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New combo therapy shows promise against hepatitis b
Disease control CompletedThis study tested an experimental drug called VIR-2218, given alone or with another medicine (pegylated interferon), in 84 adults with chronic hepatitis B. The goal was to check safety and how well the drug fights the virus. Participants received injections and were monitored for…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New hope for hepatitis b: experimental therapies aim to suppress the virus
Disease control CompletedThis study tested new experimental treatments for adults with chronic hepatitis B, a long-term liver infection. A total of 33 participants received different combinations of investigational drugs. The main goal was to see if these treatments could lower the virus to undetectable …
Phase: PHASE1, PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 05, 2026 12:05 UTC